A Pilot Study in Severe Patients With Takayasu Arteritis.
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age14-100
SponsorShanghai Zhongshan Hospital
About this trial
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.
Eligibility criteria
Qualifiers
age≥14 years old;
active: Kerr score≥ 2;
Blood pressure > 180/110mmHg;
≥ 3 branches with the stenotic rate > 70% involved;
Disqualifiers
Severe organ insufficiency;
Acute or chronic active infections including tuberculosis, hepatitis virus, etc.;
Other autoimmune diseases including systemic lupus erythematosus, Behcet disease, IgG4 relative disease;
malignant tumors;
Trial design
Treatments tested in this trial
- Tocilizumab
- Adalimumab
Treatment groups
40 Participants
are divided into 2 treatment groupsLocations
1Department of Rheumatology in Zhongshan hospital, Fudan University200032, ShanghaiShanghai Municipality, China
Sponsors and collaborators
Shanghai Zhongshan Hospital
Lead sponsor
Source ClinicalTrials.gov